Seegene, Samsung Enter Cancer MDx Pact | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Seegene and Samsung Medical Center today said they will collaborate to develop new molecular diagnostics tests directed at cancer.

The partnership combines Seegene's MDx technology with Samsung's clinical and disease pathology expertise, the two firms said. They added that Samsung will provide the first test sites for the diagnostic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.